Xiang Yao Su

Wenzhou Medical University — China

Medicine · Health Sciences

11h-index739citations64works3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(21), Acute Myeloid Leukemia Research(15), Cell death mechanisms and regulation(9), Chronic Myeloid Leukemia Treatments(9), Acute Lymphoblastic Leukemia research(7)

Publications64 total

GDF11 Regulates Vascular Smooth Muscle Cell Phenotype Switching to Prevent Aortic Aneurysm Formation
Cardiovascular Drugs and Therapy·2025
pH-responsive bilayer hydrogel with sequential release of morin-based nanoparticles and bFGF for the treatment of the “ice and fire” wounds
Materials Today Bio·2025· 1 citedOpen Access
Engineering biomimetic nanovesicles for <scp>PEBP1 mRNA</scp> delivery to inhibit ferroptosis in abdominal aortic aneurysm
Bioengineering & Translational Medicine·2025· 1 citedOpen Access
Prophylactic Dose of Rivaroxaban Versus Warfarin for the Treatment of Isolated Calf Muscle Vein Thrombosis: A Retrospective Propensity Score-Matched Analysis
Annals of Vascular Surgery·2024· 1 cited
All-in-one hydrogel patches with sprayed bFGF-loaded GelMA microspheres for infected wound healing studies
International Journal of Pharmaceutics·2024· 15 citedOpen Access
Commentary on “Ultrasmall polyvinylpyrrolidone-modified iridium nanoparticles with antioxidant and anti-inflammatory activity for acute pancreatitis alleviation”
Journal of Clinical and Experimental Hematology·2024
Ultrasmall polyvinylpyrrolidone‐modified iridium nanoparticles with antioxidant and anti‐inflammatory activity for acute pancreatitis alleviation
Journal of Biomedical Materials Research Part A·2024· 9 citedOpen Access
Figure S2 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
2023Open Access
Table S1 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
2023Open Access
Figure S5 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
2023Open Access
Data from A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses
2023Open Access
Data from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
2023Open Access
Figure S5 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
2023Open Access
Table S2 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
2023Open Access
Figure S3 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
2023Open Access
Figure S4 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
2023Open Access
Table S1 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
2023Open Access
Figure S1 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
2023Open Access
Table S2 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
2023Open Access
Supplementary Tables S1-S5 from A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Harold Keer(16), Aram Oganesian(16), Simone Jueliger(16), Monica Mita(14), Patricia LoRusso(14), Kyriakos P. Papadopoulos(14), Alain C. Mita(14), Roberta Ferraldeschi(14), Anthony W. Tolcher(14), Gail J. Roboz(12), Hagop M. Kantarjian(12), Jean‐Pierre J. Issa(12), Patricia Kropf(9), Mohammad Azab(9), Woonbok Chung(8), Andrew D. Kelly(7), Henry C. Fung(7), Jaroslav Jelı́nek(7), Michael S. Gordon(6), Mohammad Azab(5)